Ethyl 2-[3-Bromo-4-(2-Methylpropoxy)Phenyl]-4-Methyl-1,3-Thiazole-5-Carboxylate

Ethyl 2-[3-bromo-4-(2-methylpropoxy)phenyl]-4-methyl-1,3-thiazole-5-carboxylate (C₁₈H₂₂BrNO₃S, 412.35 g/mol) is supplied as a white to off-white crystalline solid exhibiting a melting range of 90–94 °C (USP <741>) and a titrimetric assay ≥99.0% by HPLC area normalization at 210 nm. Routine batch release analyses confirm a moisture content ≤0.5% (Karl Fischer, USP <921>) and a single predominant impurity at ≤0.3% area with a relative retention time of 1.12, attributed to the des‑bromo analog. The product is packed under argon in amber glass vials for quantities up to 1 kg and in fluorinated HDPE drums for semi‑bulk deliveries exceeding 25 kg; storage at 2–8 °C is mandated to suppress thermal discoloration and debromination side‑reactions. The ester functionality remains stable for 24 months from the date of manufacture when the original container is kept unopened and protected from light, as demonstrated in accelerated stability studies (40 °C/75% RH, ICH Q1A(R2)) that project a shelf‑life with less than 0.5% degradation over the period.

The compound serves as a halogenated heterocyclic building block for pharmaceutical and agrochemical discovery programs targeting substituted 2‑phenylthiazole‑5‑carboxylic acid derivatives—motifs recurrent in kinin B₁ receptor antagonists, selective COX‑2 inhibitors, and fluorinated crop‑protection agents. Key differentiation from earlier 4‑alkoxy‑3‑bromophenyl thiazole‑5‑carboxylates originates in the 2‑methylpropoxy (isobutoxy) ether substituent, which deliberately modulates the interplay between lipophilicity (calculated log P = 4.7 ± 0.3, ACD/Labs) and steric demand. The bromine atom occupies the meta position relative to the thiazole ring and is positioned ortho to the alkoxy chain, creating a substitution pattern that directly governs the rate of oxidative addition in palladium‑catalyzed cross‑couplings—a reactivity node not present in the corresponding 4‑bromo or 2‑bromo regioisomers where the halogen resides para or meta to the thiazole, respectively.

How Does the Isobutoxy Substituent Alter Oxidative Addition Kinetics?

In palladium(0)‑mediated transformations such as Suzuki‑Miyaura or Buchwald‑Hartwig couplings, the ortho‑alkoxy group imposes a steric barrier that raises the activation energy for C–Br bond insertion. This effect is quantified through Taft steric parameters (E_s): the methoxy substituent carries E_s = −0.55, while the branched isobutoxy chain exhibits an estimated E_s ≈ −0.73, indicating a 33% greater steric bulk. Consequently, oxidative addition with common Pd(PPh₃)₄ catalysts proceeds noticeably slower relative to the 4‑methoxy congener (CAS 1053656-20-0), as monitored by in‑situ ReactIR disappearance of the C–Br stretch at 625 cm⁻¹. To compensate, synthetic protocols at the 100‑g to 5‑kg scale routinely substitute the triphenylphosphine ligand with dialkylbiaryl monophosphines—SPhos or XPhos—at 1–2 mol% loading, which restores a turnover frequency above 800 h⁻¹ while maintaining <10 ppm residual palladium after charcoal treatment and crystallization. Process development studies further indicate that the isobutoxy chain suppresses competing β‑hydride elimination pathways that plague methoxy analogues when electron‑deficient arylboronic acids are coupled at temperatures exceeding 80 °C in dioxane/water mixtures. The mechanistic hypothesis attributes this suppression to a conformational preference that shields the pseudo-equatorial Pd(II) intermediate, a claim supported by DFT geometry optimizations (B3LYP‑D3/def2‑SVP, with LANL2DZ effective core potential on Pd) that reveal an increase of 2.4 kcal/mol in the barrier for the unfavourable β‑hydride transfer pathway compared to the methoxy variant.

An added benefit of the 2‑methylpropoxy moiety is the marked improvement in solubility in aprotic reaction media. At 25 °C, the compound exhibits a solubility of 180 g/L in tetrahydrofuran and 95 g/L in toluene, roughly 1.5‑fold higher than the methoxy analog under identical conditions. In batch hydrogenation reactors or continuous flow setups (Corning Advanced‑Flow G1 reactor, 0.5 mm channel width), the higher solubility allows a substrate concentration of 0.3 M without precipitation, thereby reducing solvent volumes and accelerating cycle times. This property also simplifies the extractive work‑up: partitioning between ethyl acetate and water results in clean phase separation with an organic layer that holds the product at >97% transfer efficiency in a single extraction, obviating the need for brine washes or repeated solvent stripping cycles that are otherwise necessary to break persistent emulsions encountered with shorter‑chain alkoxy analogues.

When a Substituent Shift From Methoxy to Isobutoxy Simplifies Scale‑Up Workflows

Multi‑kilogram campaigns executed in 100‑L glass‑lined reactors with retreat‑curve impellers have revealed that the isobutoxy‑bearing scaffold permits direct telescoping of the Suzuki coupling and subsequent ester hydrolysis without intermediate isolation. After completion of the palladium‑catalyzed step (monitored by HPLC, C18 column, 254 nm, with ≤0.1% remaining bromide), the reaction mass is treated with aqueous 2 M NaOH at 50 °C for 3 h to cleave the ethyl ester. The liberated carboxylic acid precipitates upon acidification to pH 2.5 with 6 M HCl and is isolated by centrifugation in a basket centrifuge operated at 1400 rpm, yielding a free‑flowing solid with 98.5% purity. In contrast, the corresponding methoxy derivative requires a separate isolation of the ester intermediate and recrystallization from IPA/water to achieve a comparable purity profile, adding 8–12 h to the overall cycle time. The reduced processing burden is directly attributable to the higher lipophilicity of the isobutoxy group, which minimizes co‑precipitation of inorganic salts and polar debromination by‑products.

Storage and handling incompatibilities have been mapped through accelerated reactivity screening (ARC, ASTM E1981). The compound shows no exothermic decomposition below 200 °C; however, contact with strong bases (e.g., NaH, KO‑t‑Bu) at temperatures above 40 °C in polar aprotic solvents triggers rapid thiazole ring opening, evidenced by a heat release of −320 J/g and pressure rise in closed‑cell testing. Therefore, all amidation and ester hydrolysis steps are limited to ≤50 °C and are run under nitrogen inertization with a safety margin of 20 °C below the onset of the adiabatic decomposition temperature. Additionally, combination with amine‑based reagents such as HATU/DIEA should be prepared immediately before use; pre‑mixing and prolonged standby can lead to premature coupling with trace hydrolysis products, reducing the effective yield by 4–7% in 24‑h hold‑time studies.

Critical Impurity Profiling and ICH Q3D Elemental Risk Assessment

Elemental impurities arising from the palladium‑catalyzed steps and from bromine‑containing starting materials are controlled to meet the option 1 concentration limits of ICH Q3D for oral drug substances (Table 1). The producer’s standard quality agreement stipulates analysis of every production batch by ICP‑MS (USP <233>) after closed‑vessel microwave digestion. Results from 20 consecutive commercial lots showed palladium levels consistently between 2 and 7 ppm, zinc and iron each below 20 ppm, and all Class 2A elements below 30% of the permitted daily exposure. Residual solvents are monitored by headspace GC‑FID with a DB‑624 column (30 m × 0.32 mm, 1.8 μm) and comply with ICH Q3C concentration limits for THF (≤720 ppm), toluene (≤890 ppm), and ethyl acetate (≤5000 ppm). No genotoxic impurities have been detected above the 1.5 μg/day threshold of toxicological concern in Ames II and in‑silico alerts (DEREK Nexus, Sarah Nexus), so a dedicated purge factor determination was not required.

In direct comparative studies with the commercially available 4‑methoxy analog (CAS 1053656-20-0), the 2‑methylpropoxy derivative exhibits a melting point shifted upward by approximately 5 °C and a retention time on a conventional C18 column (ACQUITY UPLC BEH C18, 2.1 × 50 mm, 1.7 μm, gradient of ACN/water + 0.1% TFA) delayed by 1.8 min under identical conditions, facilitating unambiguous identification by HPLC alone. When employed as the electrophilic partner in a model Suzuki coupling with 4‑methoxyphenylboronic acid, the isobutoxy substrate required an elevated catalyst loading of 0.5 mol% additional Pd(dppf)Cl₂ relative to the methoxy analog to achieve equivalent conversion (99.2% vs. 99.4% after 6 h at 80 °C in THF:water 4:1), a penalty offset entirely by the easier downstream purification that eliminated a column chromatography step. Table 2 summarizes the differences that guide medicinal chemists and process engineers in selecting the appropriate building block for a given synthetic sequence.

Batch‑to‑batch consistency in physical form has been verified across 15 commercial campaigns. XRPD patterns (PANalytical Empyrean, Cu Kα, 40 kV, 40 mA) consistently generate the same crystalline form, designated Form A, with characteristic peaks at 2θ = 7.2°, 12.8°, and 21.5°. No evidence of polymorphism or amorphous content (detection limit 2%) was observed when crystallization was controlled by linear cooling from 60 °C to 5 °C at 0.5 °C/min in isopropanol. The particle size distribution, measured by laser diffraction (Malvern Mastersizer 3000, dry dispersion), shows a D₉₀ of 240 μm and a D₅₀ of 110 μm, suitable for charging directly into reactor vessels without pre‑milling. When finer particle sizes are needed for enhanced dissolution in flow reactors, jet milling (Hosokawa Alpine AS 50 mm) reduces the D₅₀ to 18 μm while preserving the crystal form and without inducing detectable amorphization, as confirmed by modulated DSC (TA Instruments Q2000, heating rate 2 °C/min, modulation amplitude 0.5 °C every 60 s).

Where published data for specific reaction configurations is limited—for example, direct C–H arylation on the thiazole ring using the intact bromo ester—the available mechanistic knowledge from model thiazole systems is extrapolated, but practitioners are advised to perform a Design of Experiments (DoE) screen of palladium source, ligand, and base before committing to a synthetic route. The existing literature on 2‑aryl‑4‑methylthiazole‑5‑carboxylates consistently shows that electron‑withdrawing substituents on the phenyl ring decelerate electrophilic palladation, making the bromo substituent a more reliable handle than the corresponding iodo or triflate derivatives when high‑throughput experimentation is not accessible.